Anzeige
Mehr »
Freitag, 14.11.2025 - Börsentäglich über 12.000 News
Trump. Zölle. Craig Parry. Vizsla Copper wird zur strategisch wichtigsten Kupferaktie Nordamerikas
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7QK | ISIN: GB0034330679 | Ticker-Symbol: DWV
Frankfurt
14.11.25 | 08:00
0,020 Euro
0,00 % 0,000
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
CELLBXHEALTH PLC Chart 1 Jahr
5-Tage-Chart
CELLBXHEALTH PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0190,02121:12

Aktuelle News zur CELLBXHEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CELLBXHEALTH Aktie jetzt für 0€ handeln
05.11.CellbxHealth seeks to raise £6m as cash runway extends to early 20261
05.11.Cellbxhealth PLC - Further Update on Funding-
05.11.CelLBxHealth presents proof-of-concept study using Roche workflow9
05.11.CelLBxHealth belegt Kompatibilität mit Roche-Diagnostiksystem in Proof-of-Concept-Studie14
05.11.CelLBxHealth PLC Presents Proof-of-Concept Study129CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development conferenceParsortix platform shown to be compatible with the Roche BenchMark ULTRA...
► Artikel lesen
05.11.Cellbxhealth PLC - CelLBxHealth Presents Proof-of-Concept Study1
04.11.Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding149Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation TechnologyExpert consensus predicts integration of CTC testing into routine...
► Artikel lesen
29.10.ANGLE plc changes name to CelLBxHealth, updates stock ticker3
29.10.Angle PLC - Change of Name1
27.10.AIM Market Roundup: Angle, Coyngar, Light Science Technologies1
16.10.IN BRIEF: Angle names Peter Collins as interim CEO2
16.10.Angle Appoints Peter Collins As Interim CEO1
16.10.ANGLE plc Announces Appointments: Interim CEO and Senior Board Advisor196GUILFORD, SURREY / ACCESS Newswire / October 16, 2025 / ANGLE plc (to be renamed CelLBxHealth plc) (AIM:AGL)(OTCQX:ANPCY), a world-leading circulating tumour cell (CTC) intelligence company with tests...
► Artikel lesen
08.10.Angle touts planned name and strategy change, Groen turns executive11
08.10.Angle PLC Announces Strategy Update173Appointment of Executive Chairman, proposed change of name and strategy updateCompany to pursue revised strategy and name change to CelLBxHealth plcDr. Jan Groen, the current Non-Executive Chairman...
► Artikel lesen
29.09.Angle PLC Announces Presentation of Data on Glioblastoma197CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma PatientsGBM CTC isolation only possible with Parsortix label-free methodologyData presented at the 7th ACTC meeting GUILDFORD, SURREY / ACCESS...
► Artikel lesen
29.09.Angle: Presentation of Data on Glioblastoma-
12.09.IN BRIEF: Angle CEO and finance lead step down after shareholder talks1
12.09.Angle founder and CEO steps down after shareholder backlash1
12.09.Angle CEO and finance director resign2
Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1